A Phase 2a Randomized, Double-blinded, Double Dummy, Placebo And Active Controlled, Two-way Cross-over, Flare-enriched Multi-centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A Fatty Acid Amide Hydrolase (Faah) Inhibitor Pf-04457845 In Patients With Osteoarthritis Of The Knee.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs JZP 150 (Primary) ; Naproxen
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 16 Oct 2012 Planned number of patients changed from 130 to 145 as reported by European Clinical Trials Database record.
- 01 Sep 2012 Status changed from completed to discontinued.
- 02 Sep 2010 An abstract explaining trial design rationale was presented at the 13th World Congress of Pain. Interim results were also presented.